The present disclosure discloses a method for preparation of derivatives of gram-positive bacteria surface capsular polysaccharide, and belongs to the field of carbohydrate chemistry. The present disclosure takes glucose as a glycosyl donor to obtain a target -glucosidic bond, then successfully synthesizes a disaccharide building block through a method of redox of a glucose C-2 site, and then takes the disaccharide building block as a repeat unit to synthesize a target oligosaccharide structure such as a derivative [.fwdarw.3)--D-Manp-(1.fwdarw.4)--D-Rhap-(1.fwdarw.].sub.5-Linker of gram-positive bacteria cell wall capsular polysaccharide. A reduction end of decose is linked with a linker to be linked with a protein to make glycoconjugates for immunological studies. The method provided by the present disclosure is simple, time-saving, labor-saving and low-cost, and the resultant derivatives of the gram-positive bacteria surface capsular polysaccharide may be used for development and preparation of medicine related to autism.

The present disclosure relates to sugar-linked amino acids and processes for preparing the same. The sugar-linked amino acids may be used for solid-phase peptide synthesis. A sugar compound and an amino acid compound having a nucleophilic side chain are reacted in a heated halogenated solvent. The reaction is catalyst by a Lewis acid, such as InBr.sub.3. The reaction is performed as a batch or continuous process.

The present disclosure relates to sugar-linked amino acids and processes for preparing the same. The sugar-linked amino acids may be used for solid-phase peptide synthesis. A sugar compound and an amino acid compound having a nucleophilic side chain are reacted in a heated halogenated solvent. The reaction is catalyst by a Lewis acid, such as InBr.sub.3. The reaction is performed as a batch or continuous process.

The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

Provided in the present invention are a class of Lincomycin biosynthetic intermediates and a preparation method and use thereof. Specifically provided are Lincomycin biosynthetic intermediates obtained from the genetic modification of a Lincomycin producing bacterium, and a method for the production thereof through fermentation and purification through separation.

Provided in the present invention are a class of Lincomycin biosynthetic intermediates and a preparation method and use thereof. Specifically provided are Lincomycin biosynthetic intermediates obtained from the genetic modification of a Lincomycin producing bacterium, and a method for the production thereof through fermentation and purification through separation.

The present invention provides nonionic cleavable surfactants (NCS), specifically n-Decyl-disulfide--D-maltoside (DSSM), suitable for MS-based proteomics and analysis. These surfactants are designed to mimic the properties of a commonly used surfactant in structural biology, n-dodecyl--d-maltoside (DDM), but contain a disulfide bond that allows for facile cleavage and surfactant removal before analysis. DSSM and other NCS are compatible with native mass spectrometry, top-down and bottom-up proteomics, ESI-MS and other analytical techniques, and reduce signal suppression typically observed with other surfactants. DSSM and other NCS provide versatile surfactants that can facilitate protein sample preparation under non-denaturing conditions for a myriad of proteomic and structural biology applications and act as a general replacement for DDM.